Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
AstraZeneca
M.D. Anderson Cancer Center
FindCure Biosciences (ZhongShan) Co., Ltd.
Kaiser Permanente
Fred Hutchinson Cancer Center
Solve Therapeutics
University of Nebraska
Adela, Inc
Eli Lilly and Company
Degron Therapeutics Co.
National Cancer Institute (NCI)
Bayer
UNC Lineberger Comprehensive Cancer Center
The University of Texas Health Science Center at San Antonio
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Azienda Ospedaliera di Padova
SOLTI Breast Cancer Research Group
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Children's Hospitals and Clinics of Minnesota
Rutgers, The State University of New Jersey
Taproot Health
TransThera Sciences (Nanjing), Inc.
UNICANCER
M.D. Anderson Cancer Center
Hoffmann-La Roche
Genmab
Kineta Inc.
Institut Bergonié
MacroGenics
Celgene
Mayo Clinic
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Novartis
Memorial Sloan Kettering Cancer Center
Stanford University
Valerio Therapeutics